Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Tirzepatide in Renal Impairment
NCT03482024Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2018
- Primary completion
- Aug 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of tirzepatide in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to Tlast, Maximum Concentration and 1 more. Started Mar 2018; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03482024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03482024.